Deals this week: OrthoSpin, Thornhill Medical, Medigus

27 July 2018 (Last Updated July 26th, 2018 11:58)

OrthoSpin Ltd has raised $3m in a financing round from US-based investment firm Johnson & Johnson Innovation - JJDC Inc.

OrthoSpin Ltd has raised $3m in a financing round from US-based investment firm Johnson & Johnson Innovation – JJDC Inc.

Based in Israel, OrthoSpin is focused on the development of a robotic external fixation system to improve patient care.

The company plans to use the funds towards clinical trials.

Thornhill Medical has raised funds through a series A financing round from China-based investment firm Shanghai Yonghua Investment Management Co Ltd.

Based in Canada, Thornhill Medical manufactures novel healthcare products.

The company plans to use the funds towards working capital, clinical development, and to expand its footprint and sales in the international market.

Medigus Ltd has raised $10m through an underwritten public offering of 2.8 million units priced at $3.5 a unit.

Each unit consists of an American depositary share (ADS) and a series C ADS purchase warrant, which permits the holder to acquire one additional ADS at a price of $3.5 within five years of the offer closure.

HC Wainwright & Co has been appointed as the sole book-running manager for the offering.

Based in Israel, Medigus is engaged in the manufacture of surgical endostaplers and direct vision systems for medical procedures.

The company plans to use the funds towards general corporate purposes.

“The asset transaction will enable the acquirer company to improve the supply of insulin delivery systems for diabetes patients.”

CeQur SA has completed the acquisition of certain assets from Johnson & Johnson Diabetes Care Companies’ (JJDCC) subsidiary Calibra Medical Inc.

CeQur will acquire a worldwide license for the insulin delivery system OneTouch Via. The device is expected to be launched by CeQur in 2019, pursuant to the transfer of manufacturing equipment.

Based in Switzerland, CeQur is engaged in the manufacture of insulin delivery devices, while Calibra Medical is a US-based developer of three-day, wearable, on-demand bolus insulin-delivery device.

The asset transaction will enable the acquirer company to improve the supply of insulin delivery systems for diabetes patients.

Viz.ai has raised $21m through a series A financing round from Kleiner Perkins and venture financing firm GV.

Based in the US, Viz.ai is a healthcare company engaged in the development of applied artificial intelligence (AI) software for physicians and healthcare units.

The company plans to expand its product portfolio.

Beijing Allcure Medical Technology Co Ltd has raised CNY700m ($103.26m) through a series B financing round from China Capital Investment Group Co Ltd.

China Health Industry Investment Fund Co Ltd, Shanghai Jinpu Jiangfu Equity Management, and other investors also participated in the funding round.

Based in China, Beijing Allcure Medical Technology specialises in radiotherapy and tumour diagnosis.

The company plans to use the funds towards the development of tumour radiotherapy.